A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer

Trial Profile

A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Cixutumumab (Primary) ; Vismodegib (Primary) ; Cisplatin; Etoposide
  • Indications Small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 10 May 2016 Interim results (n=143) published in the Cancer
    • 15 Aug 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
    • 25 Jul 2013 Planned end date changed from 1 Aug 2022 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top